STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells

Clinical Cancer Research

Volumn 14, Issue 2, 2008, Pages 597-606

  Newman, Simon P ^a   Foster, Paul A ^a   Stengel, Chloe ^a   Day, Joanna M ^a   Ho, Yaik T ^a   Judde, Jean Gabriel ^b   Lassalle, Myriam ^b   Prevost, Gregoire ^c   Leese, Mathew P ^d   Potter, Barry V L ^d   Reed, Michael J ^a   Purohit, Atul ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b XenTech   (France)

^c Institut Henri Beaufour   (France)

^d University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; 2 METHOXYESTRADIOL 3,17 O,O BISSULFAMATE; DOCETAXEL; ESTRADIOL DERIVATIVE; PACLITAXEL; STX 140; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTRENES; HUMANS; MICE; MICE, NUDE; P-GLYCOPROTEIN; PACLITAXEL; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 38949192004     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1717     Document Type: Article

References (44)

1. Ring AE, Ellis PA. Taxanes in the treatment of early breast cancer. Cancer Treat Rev 2005;31:618-27.
2. Berrieman HK, Lind MJ, Cawkwell L. Do β-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 2004;5:158-64.
3. Monzo M, Rosell R, Sanchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with β-tubulin gene mutations. J Clin Oncol 1999;17:1786-93.
4. Kelley MJ, Li S, Harpole DH. Genetic analysis of the β-tubulin gene, TUBB, in non-small-cell lung cancer. J Natl Cancer Inst 2001;93:1886-8.
5. Zhang CC, Yang JM, White E, Murphy M, Levine A, Hait WN. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to Vinca alkaloids in p53 mutant cells. Oncogene 1998;16:1617-24.
6. Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 2002;62:6864-9.
7. Curmi PA, Nogues C, Lachkar S, et al. Overexpression of stathmin in breast carcinomas points out to highly proliferative tumors. Br J Cancer 2000;82:142-50.
8. Fojo AT, Menefee M. Microtubule targeting agents: basic mechanisms of multidrug-resistance (MDR). Semin Oncol 2005;32:S3-8.
9. Burkhart CA, Kavallaris M, Band Horwitz S. The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001;1471:O1-9.
10. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62.
11. Chevillard S, Vielh P, Vallidire P, Robert J, Marie JP. [A study of the expression of MDR1 gene in solid tumors. Initial results of a multicenter evaluation]. Bull Cancer 1996;83:626-33.
12. Filipits M, Suchomel RW, Dekan G, et al. MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 1996;2:1231-7.
13. Mechetner E, Kyshtoobayeva A, Zonis S, et al. Levels of multidrug-resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to Taxol and doxorubicin. Clin Cancer Res 1998;4:389-98.
14. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003;8:411-24.
15. Modok S, Mellor HR, Callaghan R. Modulation of multidrug-resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 2006;6:350-4.
16. de Jonge M, Verweij J. The epothilone dilemma. J Clin Oncol 2005;23:9048-50.
17. Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997;57:3208-13.
18. Funahashi Y, Koyanagi N, Kitoh K. Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine Colon 38 tumor. Cancer Chemother Pharmacol 2001;47:179-84.
19. Morton CL, Favours EG, Mercer KS, et al. Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs 2007;25:285-95.
20. Fox E, Maris JM, Widemann BC, et al. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 2006;12:4882-7.
21. Yamamoto K, Noda K, Yoshimura A, Fukuoka M, Furuse K, Niitani H. Phase I study of E7010. Cancer Chemother Pharmacol 1998;42:127-34.
22. Hande KR, Hagey A, Berlin J, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 2006;12:2834-40.
23. Newman SP, Ireson CR, Tutill HJ, et al. The role of 17β- hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells. Cancer Res 2006;66:324-30.
24. Ireson CR, Chander SK, Purohit A, et al. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br J Cancer 2004;90:932-7.
25. Crown J, O'Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 2004;9:24-32.
26. Marchetti P, Urien S, Cappellini GA, Ronzino G, Ficorella C. Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol Hematol 2002;44:S3-13.
27. Chander SK, Foster PA, Leese MP, et al. In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. Br J Cancer 2007;96:1368-76.
28. Leese MP, Leblond B, Smith A, et al. 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem 2006;49:7683-96.
29. Raobaikady B, Reed MJ, Leese MP, Potter BVL, Purohit A. Inhibition of MDA-MB-231 cell cycle progression and cell proliferation by C-2-substituted oestradiol mono-and bis-3-O-sulphamates. Int J Cancer 2005;117:150-9.
30. Newman SP, Leese MP, Purohit A, et al. Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. Int J Cancer 2004;109:533-40.
31. Ho YT, Newman SP, Purohit A, Leese MP, Potter BVL, Reed MJ. The effects of 2-methoxy oestrogens and their sulphamoylated derivatives in conjunction with TNF-α on endothelial and fibroblast cell growth, morphology and apoptosis. J Steroid Biochem Mol Biol 2003;86:189-96.
32. Day JM, Newman SP, Comninos A, et al. The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells. J Steroid Biochem Mol Biol 2003;84:317-25.
33. Suzuki RN, Newman SP, Purohit A, Leese MP, Potter BVL, Reed MJ. Growth inhibition of multidrug-resistant breast cancer cells by 2-methoxyoestradiol- bis-sulphamate and 2-ethyloestradiolbis-sulphamate. J Steroid Biochem Mol Biol 2003;84:269-78.
34. Marangoni E, Vincent-Salomon A, Auger N, et al. A new model of patient-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007;13:3989-98.
35. Leese MP, Hejaz HA, Mahon MF, et al. A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents. J Med Chem 2005;48:5243-56.
36. Abdul-Ghani R, Serra V, Gyorffy B, et al. The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 2006;25:1743-52.
37. Dahut WL, Lakhani NJ, Gulley JL, et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 2006;5:22-7.
38. James J, Murry DJ, Treston AM, et al. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 2007;25:41-8.
39. Castedo M, Perfettini JL, Roumier T, Kroemer G. Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 2002;9:1287-93.
40. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res 1997;57:81-6.
41. Chen JS, Konopleva M, Andreeff M, Multani AS, Pathak S, Mehta K. Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis. J Cell Physiol 2004;200:223-34.
42. Chorna I, Bilyy R, Datsyuk L, Stoika R. Comparative study of human breast carcinoma MCF-7 cells differing in their resistance to doxorubicin: effect of ionizing radiation on apoptosis and TGF-β production. Exp Oncol 2004;26:111-7.
43. Ueda K, Taguchi Y, Morishima M. How does P-glycoprotein recognize its substrates? Semin Cancer Biol 1997;8:151-9.
44. Gokmen-Polar Y, Escuin D, Walls CD, et al. β-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer Res 2005;65:9406-14.